Qbrexza was Journey Medical’s largest product and service line in fiscal 2025, bringing in $25.01M of $61.24M (41%).
| Product and Service | FY 2020 | FY 2021 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Targadox | — | — | ||
| Qbrexza | $25.11M | $25.01M | ||
| Qbrexa | — | — | ||
| Emrosi | — | $14.75M | ||
| Accutane | $19.41M | $12.88M | ||
| Ximino | — | — | ||
| Foam Franchise Products (Amzeeq Zilxi) | $6.65M | $5.86M | ||
| Exelderm | — | — | ||
| Other / Legacy | $3.96M | $2.74M | ||
| Other Branded Products | — | — | ||
| Total | $55.13M | $61.24M |
Journey Medical brought in $61.24M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. Journey Medical regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $55.13M. Qbrexza was the largest at $25.01M (40.8%), ahead of Emrosi at $14.75M (24.1%) and Accutane at $12.88M (21.0%). The other two lines brought in $8.60M combined.
Compared with fiscal 2024, every line above 2% of revenue shrank. Qbrexza held up best, down 0.4% to $25.01M, and Accutane fell the most, down 33.6% to $12.88M.
Journey Medical began breaking out Emrosi in fiscal 2025, when it brought in $14.75M.
Journey Medical (DERM) reports its revenue by product and service. In fiscal 2025, Qbrexza was its largest product and service line, bringing in $25.01M (40.8% of the total), followed by Emrosi at $14.75M (24.1%).
Qbrexza was Journey Medical's largest product and service line in fiscal 2025, bringing in $25.01M, or 40.8% of the $61.24M total across its five product and service lines.
Every figure comes from Journey Medical's annual financial filings, as reported. Each line keeps the name Journey Medical gives it, and years follow its fiscal calendar.
Journey Medical's revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.